Pharmanutra, new agreements signed for the foreign market

PharmaNutra in 2022 revenues 215 profit 13

(Tiper Stock Exchange) – PharmaNutraa company specializing in the sector of nutritional supplements and medical devices for muscles and joints, announces the closing of three important new distribution contracts abroad.

Specifically, the agreements concern the products of the SiderAL line, a food supplement based on Sucrosomial Iron, created on the basis of Sucrosomial Technology, an innovative delivery system capable of protecting micronutrient molecules such as iron, increasing their absorption and improving their tolerability.

The first agreement concerns the Benelux and was signed with GLNP Pharma, a Dutch company specializing in the development and sale of nutritional supplements dedicated to body health and biomedical equipment, already in partnership with Akern Srl, a company that recently joined the PharmaNutra Group. Starting from the month of June, GLNP Pharma will take care of the distribution on the territory of the SiderAL Forte.

The second agreement was signed with Laboratorio Aristona company already in partnership with the PharmaNutra Group for the distribution in Argentina del SiderAL Forte: a consolidated reality engaged in the development, production and marketing of pharmaceutical products, Laboratorio Ariston will expand its distribution in Chile and Uruguay, considerably strengthening the presence of PharmaNutra in the South American continent.

KOL Pharma, a company active in the distribution of medical devices in the Americas, will instead distribute two products of the SiderAL line in Central America, specifically SiderAL Forte and SiderAL Folic, which will soon also be available in Guatemala, Panama, El Salvador and Costa Rica . An agreement that further contributes to consolidating PharmaNutra’s presence on the Latin American market, which is constantly growing and with prospects for further development with the launch of the new PharmaNutra USA.

tlb-finance